Genetic polymorphisms of CYP1A2 have been identified as leading to interindividual variation in the susceptibility to a series of cancer, such as cholangiocarcinoma, lung, colorectal and breast cancer [11–15]. This evidence concerns the gene CYP1A2 and breast carcinoma.